

February 1969 - deadly unidentified virus reported from remote African missionary hospital, two American nurses stricken and died within 10 days. Doctors stymied by mysterious symptoms of the killer: soaring temperature, painful backache, swelling of the throat and neck, discolored skin! Latest victim airlifted to special isolation ward at New York's Columbia Presbyterian Hospital, blood samples rushed to Yale's Arborvirus [sic] Laboratory, all-out search launches to discover an antidote. U. S. Public Health officials alarmed, virus has the potential to decimate the whole population, aviation officials consider cancellation of all jet travel to critical world areas.

Vol. 19, No. 4 Printed in U.S.A.

LASSA FEVER, A NEW VIRUS DISEASE OF MAN FROM WEST AFRICA

II. REPORT OF A LABORATORY-ACQUIRED INFECTION TREATED WITH Plasma from a Person Recently Recovered from the Disease

EDGAR LEIFER, DAVID J. GOCKE, AND HENRY BOURNE Department of Medicine, Columbia University College of Physicians and Surgeons, and The Presbyterian Hospital, New York, New York 10032

THE AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Copyright @ 1970 by The American Society of Tropical Medicine and Hygiene

Vol. 19, No. 4 Printed in U.S.A.

LASSA FEVER, A NEW VIRUS DISEASE OF MAN FROM WEST AFRICA

III. ISOLATION AND CHARACTERIZATION OF THE VIRUS*


SONJA M. BUCKLEY AND JORDI CASALS

Yale Arbovirus Research Unit, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510, and The Rockefeller Foundation, New York, N.Y. 10020

Table 1
Source of materials, and isolations of Lassa virus

L.W. F Lassa, Nigeria 20 Jan. Death, day 6 Serum, 26 Jan. (day 6) C.S. F Jos, Nigeria 3 Feb. Death, day 10 Serum, 6 Feb. (day 3) Serum, 13 Feb. (day 10) L.P. F Jos, Nigeria 20 Feb. Recovery Serum, 25 Feb. (day 13) Pleural fluid, 5 March (day 13) Serum, 20 March (day 13) Serum, 20 March (day 28) Serum, 29 March (day 37) J.C. M New Haven, Conn. 9 June Recovery* Serum, 16 June (day 9) Urine, 18 June (day 9) Urine, 18 June (day 9) Throat washing, 18 June (day 9) Throat washing, 23 June (day 17) Urine, 26 June (day 17) Throat washing, 23 June (day 14) Urine, 26 June (day 17) Urine, 11 July (day 32) N.Y. F — In contact with L.P. in Nigeria, Feb. '69 C.C. F — Stationed in Nigeria Serum, 23 Sept. '68 Controls		Patient Sex		Locale of infection	Date of onset, 1969	Outcome of infection	Material, and date collected		Isolation in Vero cells
L.P. F Jos, Nigeria 20 Feb. Recovery Serum, 13 Feb. (day 10) L.P. = Lily [Penny] Pinneo, RN L.P. = Lily [Penny] Pinneo, RN J.C. M New Haven, Conn. 9 June Recovery* J.C. = Jordi Casals, MD J.C. = Jordi Casals, MD Serum, 25 Feb. (day 13) Serum, 5 March (day 13) Serum, 6 March (day 13) Serum, 20 March (day 28) Serum, 29 March (day 37) Serum, 18 June (day 7) Serum, 18 June (day 9) Urine, 18 June (day 9) Urine, 18 June (day 9) Throat washing, 18 June (day 9) Throat washing, 23 June (day 14) Urine, 26 June (day 17) Urine, 11 July (day 32) N.Y. F — In contact with L.P. in Nigeria, Feb. '69 C.C. F — Stationed in Nigeria Serum, 23 Sept. '68		L.W.	F	Lassa, Nigeria	20 Jan.	Death, day 6	Serum, 26 Jan.	(day 6)	+
Serum, 5 March (day 13)	_	C.S.	F	Jos, Nigeria	3 Feb.	Death, day 10	-		+ +
Serum, 6 March (day 14) Serum, 20 March (day 28) Serum, 29 March (day 37)	L	L.P.	F	Jos, Nigeria	20 Feb.	Recovery	-		++
J.C.= Jordi Casals, MD Serum, 18 June	L.P.=	: Lily	[Pe	nny] Pinne	eo, RN		Serum, 6 March Serum, 20 March	(day 14) (day 28)	+ + + 0 0
18 June (day 9) Throat washing, 23 June (day 14) Urine, 26 June (day 17) Urine, 11 July (day 32) N.Y. F — In contact with L.P. in Nigeria, Feb. '69 C.C. F — Stationed in Nigeria Serum, 23 Sept. '68	J.C.=			·	9 June	Recovery*	Serum, 18 June Urine, 18 June	(day 9)	+ + +
N.Y. F — In contact with L.P. in Serum, 26 Feb. '69 C.C. F — Stationed in Nigeria Serum, 23 Sept. '68				,			18 June Throat washing,		+
Nigeria, Feb. '69 C.C. F — Stationed in Nigeria Serum, 23 Sept. '68							Urine, 26 June	(day 17)	+ + +
		N.Y.	N.Y. F —				Serum, 26 Feb. '69		0
Construction Distriction		C.C. Controls	F	_	Stationed	in Nigeria	Serum, 23 Sept. '68 Diluent		0

Penny with **Jordi Casals** and Raphael Adeyemi, a **Nigerian** Medical auxiliary, at the hospital in Jos, Nigeria, circa 1970.



NOTES


Arenoviruses: Proposed Name for a Newly Defined Virus Group

WALLACE P. ROWE, FREDERICK A. MURPHY, GERNOT H. BERGOLD, JORDI CASALS, JOHN HOTCHIN, KARL M. JOHNSON, FRITZ LEHMANN-GRUBE, CEDRIC A. MIMS, ERIC TRAUB, AND PATRICIA A. WEBB

National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; National Communicable Disease Center, Atlanta, Georgia; Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela; Yale University School of Medicine, New Haven, Connecticut; New York State Department of Health, Albany, New York; Middle America Research Unit, Balboa Heights, Canal Zone; Hygiene-Institut der Philipps-Universität, Marburg/Lahn, Germany; John Curtin School of Medical Research, Canberra, Australia; and United Nations Food and Agricultural Organization, Ankara, Turkey

Received for publication 23 March 1970


The name "arenoviruses" is proposed for the newly defined taxonomic group containing lymphocytic choriomeningitis, Lassa, and the Tacaribe complex viruses.




Lassa fever is a zoonosis










Whe **Africa**











Christian Happi First EVD Nigeria July 20, 2014



Lassa fever program at Kenema Government Hospital

Important site for Lassa fever research by CDC and others



International team refurbishes Lassa Laboratory



Introduction of ReLASV lateral flow immunoassays

1970s and 1980s

1993

2005

2008

2010



Blood Diamonds civil conflict forces suspension of Lassa program




Establishment of recombinant Lassa ELISA diagnostics




Lassa fever diagnosis

LASV antigen, LASV RNA or antiLASV antibody





Kenema: Early epicenter of the 2013-16 Ebola Outbreak





Healer





Dr. S. Humarr Khan



Nurse Will Pooley


Dr. Ian Crozier







■1 NEW YORK TIMES BESTSELLER





THE TERRIFYING TRUE STORY OF EBOLA OUTBREAK IN WEST AFRICA RICHARD PRESTON





Roots, Not Parachutes: Research Collaborations Combat Outbreaks

Nathan L. Yozwiak, Christian T. Happi, Donald S. Grant, John S. Schieffelin, Robert F. Garry, Pardis C. Sabeti, Kristian G. Andersen


Cell

Volume 166, Issue 1, Pages 5-8 (June 2016) DOI: 10.1016/j.cell.2016.06.029






"Confirmed" cases of Lassa fever in Nigeria



21 (of 36) states have recorded at least one confirmed case



It's all about the rodent transmission. Niger River Benue River ISTH IIB Siddle et al. NEJM, Niger River Oct. 17, 2018




Katherine Siddle



Pardis Sabeti




Christian Happi





Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits



James E. Robinson et al. Nature Communications 7 (2016) doi:10.1038/ncomms11544

Lassa virus B cell epitopes and how the work







Tom Geisbert



Bob Cross



Chad Mire




Luis Branco




Khan Center of Excellence (NIH- ICIDR)



Bilateral Hearing loss in both Ebola and Lassa fever survivors




Hearing Loss	Ebola Survivors (%)	Ebola Contacts	Lassa Survivors
Severity	n = 342	n = 850	n = 57
Normal	222 (64.9)	685 (80.6)	35 (61.4)
Mild	105 (30.7)	149 (17.5)	5 (8.8)
Moderate	11 (3.2)	14 (1.7)	4 (5.3)
Severe	3 (0.9)	2 (0.2)	2 (3.5)
Profound	1 (0.3)	0 (0.0)	12 (21.1)



Nature 526, 68–74 (01 October 2015)

DISEASES TO BE URGENTLY ADDRESSED UNDER THE R&D BLUEPRINT




Crimean-cong Hermorrhagic f virus

Thanks to Georges Thiry for pointing out that Lassa fever is one of 3 epidemic infectious diseases (with Nipah and MERS) prioritized for rapid vaccine development by the

Coalition for Epidemic Preparedness

and Innovations (CEPI). Indeed,

Lassa efficacy trials are possble!





Nipah virus Rift Valley fever virus


a new severe infectious disease

ssa fever virus

Ongoing antiLASV seroprevalence study in Sierra Leone












demographics and serology


LASV seroprevalence by age




<1 1-4 5-14 15-44 >45









Kenema District: Gateway

LIBERIA

to the Go








COTE D'IVORE

COTE D'I

Single-vector, single injection, bivalent and trivalent rVSV vaccine candidates expressing stabilized LASV GPC and EBOV GP






Bob Garry - Tulane





Matt Boisen Luis Branco



Michael Oldstone Scripps



Mombu Mamoh KGH







Erica Saphire &Kate Hastie **Scripps**







James Robinson John Schieffelin Tulane



Pardis Sabeti Harvard/ **Chad Mire & Bob Broad**



Augustine Goba KGH

Tom Geisbert

Cross UTMB



Khan - KGH



Christian Happi Redeemers

In memoriam...





